Jeremy Chataway
Overview
Explore the profile of Jeremy Chataway including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
2361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pal S, Chataway J, Swingler R, Macleod M, Carragher N, Hardingham G, et al.
Lancet Neurol
. 2024 Sep;
23(11):1097-1107.
PMID: 39307154
Background: Motor neuron disease represents a group of progressive and incurable diseases that are characterised by selective loss of motor neurons, resulting in an urgent need for rapid identification of...
12.
Blackstone J, Williams T, Nicholas J, Bordea E, De Angelis F, Bianchi A, et al.
BMJ Open
. 2024 Sep;
14(9):e086414.
PMID: 39284697
Introduction: There remains a high unmet need for disease-modifying therapies that can impact disability progression in secondary progressive multiple sclerosis (SPMS). Following positive results of the phase 2 MS-STAT study,...
13.
John N, Li Y, De Angelis F, Stutters J, Carrasco F, Eshaghi A, et al.
BMJ Neurol Open
. 2024 Sep;
6(2):e000670.
PMID: 39262426
Background: The brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain...
14.
Chataway J, Wade C, Murphy E, Lynch D
Brain
. 2024 Aug;
147(10):3271-3273.
PMID: 39110640
No abstract available.
15.
Colato E, Stutters J, Narayanan S, Arnold D, Chataway J, Wheeler-Kingshott C, et al.
Brain Commun
. 2024 Jul;
6(4):fcae234.
PMID: 39077376
In multiple sclerosis clinical trials, MRI outcome measures are typically extracted at a whole-brain level, but pathology is not homogeneous across the brain and so whole-brain measures may overlook regional...
16.
Wade C, Runeckles K, Chataway J, Houlden H, Lynch D
Neurol Genet
. 2024 Jul;
10(4):e200179.
PMID: 39040919
Background And Objectives: -related disorder (-RD) is a devastating neurodegenerative disorder caused by variants in the colony stimulating factor-1 receptor () gene. -RD leads to a variable combination of cognitive...
17.
Williams T, Lange F, Smith K, Tachtsidis I, Chataway J
Ann Clin Transl Neurol
. 2024 Jul;
11(9):2372-2381.
PMID: 39037277
Objectives: Hypoperfusion and tissue hypoxia have been implicated as contributory mechanisms in the neuropathology of multiple sclerosis (MS). Our objective has been to study cortical oxygenation in vivo in patients...
18.
Rocca M, Valsasina P, Romano F, Tedone N, Amato M, Brichetto G, et al.
J Neurol Neurosurg Psychiatry
. 2024 May;
95(12):1139-1149.
PMID: 38754979
Background: Research on cognitive rehabilitation (CR) and aerobic exercise (EX) to improve cognition in progressive multiple sclerosis (PMS) remains limited. CogEx trial investigated the effectiveness of CR and EX in...
19.
Leckey C, Coulton J, Giovannucci T, He Y, Aslanyan A, Laban R, et al.
Brain Commun
. 2024 May;
6(3):fcae132.
PMID: 38707707
Neurofilament light chain is an established marker of neuroaxonal injury that is elevated in CSF and blood across various neurological diseases. It is increasingly used in clinical practice to aid...
20.
Ramari C, DHooge M, Dalgas U, Feinstein A, Amato M, Brichetto G, et al.
Neurorehabil Neural Repair
. 2024 Mar;
38(5):327-338.
PMID: 38426484
Background: People with progressive multiple sclerosis (PMS) present motor (eg, walking) and cognitive impairments, and report fatigue. Fatigue encompasses fatigability which is objectively measured by the capacity to sustain a...